US7939102B2 - Controlled release formulation of ...- Formulation fluide de lamotrigine ,US7939102B2 US10/452,772 US45277203A US7939102B2 US 7939102 B2 US7939102 B2 US 7939102B2 US 45277203 A US45277203 A US 45277203A US 7939102 B2 US7939102 B2 US 7939102B2 Authority US United States Prior art keywords lamotrigine controlled release defined formulation particles Prior art date 2002-06-07 Legal status (The legal status is an assumption and is not a legal conclusion.US5861179A - Pharmaceutical composition of lamotrigine ...US5861179A US08/849,070 US84907097A US5861179A US 5861179 A US5861179 A US 5861179A US 84907097 A US84907097 A US 84907097A US 5861179 A US5861179 A US 5861179A Authority US United States Prior art keywords weight lamotrigine granules μm starch Prior art date 1994-12-07 Legal status (The legal status is an assumption and is not a legal conclusion.



Lamotrigine Side Effects: Common, Severe, Long Term ...

7. Page RL, ONeil MG, Yarbrough DR, Conradi S "Fatal toxic epidermal necrolysis related to lamotrigine administration." Pharmacotherapy 18 (1998): 392-8. 8. Sachs B, Ronnau AC, Ruzicka T, Gleichmann E, Schuppe HC "Lamotrigine and toxic epidermal necrolysis." Lancet 348 (1996): 1597. 9. Hilas O, Charneski L "Lamotrigine-induced Stevens-Johnson ...

Contactar al proveedor

(PDF) Therapeutic Drug Monitoring of Lamotrigine

The oral antiepileptic drug (AED), Lamotrigine (LTG), chemically 6-(2,3-dichlorophenyl)-1,2,4-triazine-3,5-diamine ( Fig. 1b) is widely used in partial seizures as well as in treatment of ...

Contactar al proveedor

Comparative evaluation of single and bilayered lamotrigine ...

Formulation LFC4 was found to be optimized with dissolution profile of zero order kinetics showing fickian diffusion. A comparative study of bilayered and single layered tablets of LM showed a highest similarity factor of 83.03, difference factor of 2.74 and t -test ( P < 0.05) indicates that there is no significant difference between them.

Contactar al proveedor

[PDF] Bimodal Gastroretentive Drug Delivery Systems of ...

Gastroretentive bimodal drug delivery systems of lamotrigine were developed using immediate release and extended release segments incorporated in a hydroxypropyl methylcellulose capsule and in vitro and in vivo evaluations were conducted. In vivo radiographic studies were carried out for the optimized formulation in healthy human volunteers with replacement of drug polymer complex by barium ...

Contactar al proveedor

Comparative evaluation of single and bilayered lamotrigine ...

Formulation LFC4 was found to be optimized with dissolution profile of zero order kinetics showing fickian diffusion. A comparative study of bilayered and single layered tablets of LM showed a highest similarity factor of 83.03, difference factor of 2.74 and t -test ( P < 0.05) indicates that there is no significant difference between them.

Contactar al proveedor

Comparative evaluation of single and bilayered lamotrigine ...

Formulation LFC4 was found to be optimized with dissolution profile of zero order kinetics showing fickian diffusion. A comparative study of bilayered and single layered tablets of LM showed a highest similarity factor of 83.03, difference factor of 2.74 and t -test ( P < 0.05) indicates that there is no significant difference between them.

Contactar al proveedor

(PDF) Therapeutic Drug Monitoring of Lamotrigine

The oral antiepileptic drug (AED), Lamotrigine (LTG), chemically 6-(2,3-dichlorophenyl)-1,2,4-triazine-3,5-diamine ( Fig. 1b) is widely used in partial seizures as well as in treatment of ...

Contactar al proveedor

ANNEX I LIST OF THE NAMES, PHARMACEUTICAL FORMS, STRENGTHS ...

Lamictal 5mg - lösliche Tabletten 5 mg Dispersible Tablet Oral use Austria GlaxoSmithKline Pharma , ... 100 Route de Versailles 78163 Marly-le-Roi Cedex France Lamicstart 25 mg, comprimé 25 mg Tablet Oral use . 11 France Laboratoire GlaxoSmithKline 100 Route de Versailles ...

Contactar al proveedor

US5861179A - Pharmaceutical composition of lamotrigine ...

US5861179A US08/849,070 US84907097A US5861179A US 5861179 A US5861179 A US 5861179A US 84907097 A US84907097 A US 84907097A US 5861179 A US5861179 A US 5861179A Authority US United States Prior art keywords weight lamotrigine granules μm starch Prior art date 1994-12-07 Legal status (The legal status is an assumption and is not a legal conclusion.

Contactar al proveedor

[PDF] Bimodal Gastroretentive Drug Delivery Systems of ...

Gastroretentive bimodal drug delivery systems of lamotrigine were developed using immediate release and extended release segments incorporated in a hydroxypropyl methylcellulose capsule and in vitro and in vivo evaluations were conducted. In vivo radiographic studies were carried out for the optimized formulation in healthy human volunteers with replacement of drug polymer complex by barium ...

Contactar al proveedor

Comparative evaluation of single and bilayered lamotrigine ...

Formulation LFC4 was found to be optimized with dissolution profile of zero order kinetics showing fickian diffusion. A comparative study of bilayered and single layered tablets of LM showed a highest similarity factor of 83.03, difference factor of 2.74 and t -test ( P < 0.05) indicates that there is no significant difference between them.

Contactar al proveedor

US5861179A - Pharmaceutical composition of lamotrigine ...

US5861179A US08/849,070 US84907097A US5861179A US 5861179 A US5861179 A US 5861179A US 84907097 A US84907097 A US 84907097A US 5861179 A US5861179 A US 5861179A Authority US United States Prior art keywords weight lamotrigine granules μm starch Prior art date 1994-12-07 Legal status (The legal status is an assumption and is not a legal conclusion.

Contactar al proveedor

Comparative evaluation of single and bilayered lamotrigine ...

Formulation LFC4 was found to be optimized with dissolution profile of zero order kinetics showing fickian diffusion. A comparative study of bilayered and single layered tablets of LM showed a highest similarity factor of 83.03, difference factor of 2.74 and t -test ( P < 0.05) indicates that there is no significant difference between them.

Contactar al proveedor

(PDF) Therapeutic Drug Monitoring of Lamotrigine

The oral antiepileptic drug (AED), Lamotrigine (LTG), chemically 6-(2,3-dichlorophenyl)-1,2,4-triazine-3,5-diamine ( Fig. 1b) is widely used in partial seizures as well as in treatment of ...

Contactar al proveedor

US7939102B2 - Controlled release formulation of ...

US7939102B2 US10/452,772 US45277203A US7939102B2 US 7939102 B2 US7939102 B2 US 7939102B2 US 45277203 A US45277203 A US 45277203A US 7939102 B2 US7939102 B2 US 7939102B2 Authority US United States Prior art keywords lamotrigine controlled release defined formulation particles Prior art date 2002-06-07 Legal status (The legal status is an assumption and is not a legal conclusion.

Contactar al proveedor

Investigation of formulation variables affecting the ...

Lamotrigine (LMG) undergoes extensive hepatic metabolism upon oral administration and its absorption is affected in the presence of food. This study was aimed to develop nanosuspension of LMG and investigate its formulation characteristics using L[9] ...

Contactar al proveedor

Investigation of formulation variables affecting the ...

Lamotrigine (LMG) undergoes extensive hepatic metabolism upon oral administration and its absorption is affected in the presence of food. This study was aimed to develop nanosuspension of LMG and investigate its formulation characteristics using L[9] ...

Contactar al proveedor

Investigation of formulation variables affecting the ...

Lamotrigine (LMG) undergoes extensive hepatic metabolism upon oral administration and its absorption is affected in the presence of food. This study was aimed to develop nanosuspension of LMG and investigate its formulation characteristics using L[9] ...

Contactar al proveedor

US7939102B2 - Controlled release formulation of ...

US7939102B2 US10/452,772 US45277203A US7939102B2 US 7939102 B2 US7939102 B2 US 7939102B2 US 45277203 A US45277203 A US 45277203A US 7939102 B2 US7939102 B2 US 7939102B2 Authority US United States Prior art keywords lamotrigine controlled release defined formulation particles Prior art date 2002-06-07 Legal status (The legal status is an assumption and is not a legal conclusion.

Contactar al proveedor

US7939102B2 - Controlled release formulation of ...

US7939102B2 US10/452,772 US45277203A US7939102B2 US 7939102 B2 US7939102 B2 US 7939102B2 US 45277203 A US45277203 A US 45277203A US 7939102 B2 US7939102 B2 US 7939102B2 Authority US United States Prior art keywords lamotrigine controlled release defined formulation particles Prior art date 2002-06-07 Legal status (The legal status is an assumption and is not a legal conclusion.

Contactar al proveedor

Investigation of formulation variables affecting the ...

Lamotrigine (LMG) undergoes extensive hepatic metabolism upon oral administration and its absorption is affected in the presence of food. This study was aimed to develop nanosuspension of LMG and investigate its formulation characteristics using L[9] ...

Contactar al proveedor

[PDF] Bimodal Gastroretentive Drug Delivery Systems of ...

Gastroretentive bimodal drug delivery systems of lamotrigine were developed using immediate release and extended release segments incorporated in a hydroxypropyl methylcellulose capsule and in vitro and in vivo evaluations were conducted. In vivo radiographic studies were carried out for the optimized formulation in healthy human volunteers with replacement of drug polymer complex by barium ...

Contactar al proveedor

[PDF] Bimodal Gastroretentive Drug Delivery Systems of ...

Gastroretentive bimodal drug delivery systems of lamotrigine were developed using immediate release and extended release segments incorporated in a hydroxypropyl methylcellulose capsule and in vitro and in vivo evaluations were conducted. In vivo radiographic studies were carried out for the optimized formulation in healthy human volunteers with replacement of drug polymer complex by barium ...

Contactar al proveedor

ANNEX I LIST OF THE NAMES, PHARMACEUTICAL FORMS, STRENGTHS ...

Lamictal 5mg - lösliche Tabletten 5 mg Dispersible Tablet Oral use Austria GlaxoSmithKline Pharma , ... 100 Route de Versailles 78163 Marly-le-Roi Cedex France Lamicstart 25 mg, comprimé 25 mg Tablet Oral use . 11 France Laboratoire GlaxoSmithKline 100 Route de Versailles ...

Contactar al proveedor